Prostate cancer Posts on Medivizor
Navigation Menu

Prostate cancer Posts on Medivizor

Comparing the effectiveness and safety of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

Comparing the effectiveness and safety of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

Posted by on May 8, 2022 in Prostate cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of abiraterone acetate (Zytiga; AA) and enzalutamide (Xtandi; ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that both medication improve outcomes compared to placebo and ENZ is more effective in improving survival without cancer...

Read More

Evaluating the risk of developing secondary rectal cancer after radiotherapy in patients with prostate cancer.

Evaluating the risk of developing secondary rectal cancer after radiotherapy in patients with prostate cancer.

Posted by on Apr 14, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the risk of developing secondary rectal cancer after radiotherapy (RT) in patients with prostate cancer. The data showed that RT significantly increased the risk of developing secondary rectal cancer in these patients. Some background Prostate cancer (PCa) is one of the most common form of cancer found in men. PCa...

Read More

Evaluating the effectiveness and safety of new antiandrogen SHR3680 in patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of new antiandrogen SHR3680 in patients with metastatic castration-resistant prostate cancer.

Posted by on Apr 10, 2022 in Prostate cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of a new hormonal therapy, SHR3680 (rezvilutamide), for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The study showed that SHR680 was well tolerated and had promising effectiveness in these patients. Some background Metastatic...

Read More

Does sipuleucel-T improve the survival of men with advanced prostate cancer treated with androgen receptor-targeting drugs?

Does sipuleucel-T improve the survival of men with advanced prostate cancer treated with androgen receptor-targeting drugs?

Posted by on Apr 10, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness of adding sipuleucel-T (Provenge) androgen receptor-targeting agents (ARTAs) such as abiraterone acetate (AA; Zytiga) and enzalutamide (Xtandi) in men with metastatic castration-resistant prostate cancer (mCRPC). The data showed that those receiving both sipuleucel-T and ARTAs were more...

Read More

Vacations for Adult Cancer Patients: Update

Vacations for Adult Cancer Patients: Update

Posted by on Mar 4, 2022 in Blog, Breast cancer, Colorectal cancer, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 0 comments

Two of our most popular previous blog posts described free vacation opportunities for adults with cancer. Given the uncertainty of the past two years, we thought it was time for an update.  Here is a short list of organizations that have made it their mission to provide needed respite to those affected by cancer. Each has been verified to have...

Read More

Evaluating the effects of enzalutamide on the health-related quality of life in patients with metastatic hormone-sensitive prostate cancer.

Evaluating the effects of enzalutamide on the health-related quality of life in patients with metastatic hormone-sensitive prostate cancer.

Posted by on Jan 30, 2022 in Prostate cancer | 0 comments

In a nutshell This study reported the long-term effects on the health-related quality of life (HR-QoL) of enzalutamide (Xtandi) in combination with androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that enzalutamide preserved the overall health and quality of life in these...

Read More

Evaluating the effectiveness and safety of docetaxel given every 2 weeks plus androgen deprivation therapy in patients with metastatic castration-naïve prostate cancer.

Evaluating the effectiveness and safety of docetaxel given every 2 weeks plus androgen deprivation therapy in patients with metastatic castration-naïve prostate cancer.

Posted by on Jan 19, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of docetaxel (Taxotere) given every 2 weeks plus androgen-deprivation therapy (ADT) in patients with metastatic castration-naïve prostate cancer (mCNPC). The data showed that docetaxel given every 2 weeks plus ADT was safe and effective in these patients. Some background MCNPC...

Read More

Comparing the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations.

Comparing the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations.

Posted by on Jan 9, 2022 in Prostate cancer | 0 comments

In a nutshell This study compared the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations in solid tumors. The data showed that PARP inhibitors could benefit both patients with BRCA1 and BRCA2 mutations with similar effectiveness. Some background BRCA1 and BRCA2 gene mutations (abnormalities) can be found in...

Read More

Using focal thermo-ablative therapy for treating oligo-recurrent prostate cancer after radiotherapy.

Using focal thermo-ablative therapy for treating oligo-recurrent prostate cancer after radiotherapy.

Posted by on Dec 31, 2021 in Prostate cancer | 0 comments

In a nutshell This study assessed patient responses to focal thermo-ablative therapy (FTA) for oligo-recurrent prostate cancer (PCa) after pelvic radiotherapy. The data suggested that FTA therapy is a good option in these patients. Some background Oligometastatic PCa means that cancer has spread to only a few places (up to 5 metastases). It...

Read More

Comparing the effectiveness and safety of apalutamide with darolutamide for non-metastatic castration-resistant prostate cancer.

Comparing the effectiveness and safety of apalutamide with darolutamide for non-metastatic castration-resistant prostate cancer.

Posted by on Dec 19, 2021 in Prostate cancer | 0 comments

In a nutshell The study compared the effectiveness and safety outcomes of androgen-deprivation therapy (ADT) with either apalutamide (Erleada) or darolutamide (Nubeqa) for the treatment of non-metastatic castration-resistant prostate cancer (CRPC). The data showed that apalutamide plus ADT was safe and more effective in improving...

Read More

Recommendations for enhancing sexual rehabilitation for survivors of prostate cancer.

Recommendations for enhancing sexual rehabilitation for survivors of prostate cancer.

Posted by on Dec 5, 2021 in Prostate cancer | 0 comments

In a nutshell This study highlights psychosocial recommendations for survivors of prostate cancer (PCa) and their partners during sexual rehabilitation. The authors concluded that biopsychosocial programs are beneficial for providing educational support and psychosocial counseling to patients with erectile dysfunction in addition to existing biomedical...

Read More

Evaluating the effectiveness of androgen receptor-targeted therapy plus radiotherapy in patients with metastatic castration resistant prostate cancer.

Evaluating the effectiveness of androgen receptor-targeted therapy plus radiotherapy in patients with metastatic castration resistant prostate cancer.

Posted by on Nov 28, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness of radiotherapy (RT) plus androgen receptor-targeted therapy (ARTT) on oligo-progressive sites for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that RT on oligo-progressive sites was safe and effective in prolonging treatment with ARTT in...

Read More